One of the most dreaded feelings for an investor is when the stock they just bought is overvalued, or they missed out on an undervalued opportunity by not acting fast enough.

But what if you had the insights to effectively evaluate a company like Exelixis Inc before investing? Investing requires a certain perspective to avoid being overly confident in a company or worried about cyclical changes. A smart way to take the guesswork out of knowing when to buy or sell Exelixis Inc’s stock is to have the right tools and resources as well as a clear monitoring process.

In this article, we go over a few key elements for understanding Exelixis Inc’s stock price such as:

• Current stock price and volume
• Stock price history
• Upgrades and downgrades from analysts
• Stock price momentum as measured by its relative strength

About Exelixis Inc (EXEL)

Before we jump into Exelixis Inc’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

Exelixis, Inc. is an oncology company. The Company is engaged in developing medicines and combination regimens at the forefront of cancer care. It has four products, including its flagship molecule, cabozantinib, which is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET. Cabozantinib is approved as CABOMETYX tablets used for advanced renal cell carcinoma (RCC), both alone and in combination with Bristol-Myers Squibb Company's (BMS) OPDIVO (nivolumab), for hepatocellular carcinoma (HCC) and for radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC). Cabozantinib is also approved as COMETRIQ capsules for metastatic medullary thyroid cancer (MTC). Its other two products are COTELLIC, an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO an oral, non-steroidal, selective blocker of the mineralocorticoid receptor (MR) approved the treatment of hypertension.

Want to learn more about Exelixis Inc’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Exelixis Inc. The AAII Stock Evaluator puts a company’s grades, charts, news, financials, valuation, ratios, filings and more at your fingertips.

Exelixis Inc’s Stock Price as of Market Close

As of March 20, 2023, 4:00 PM CST, Exelixis Inc’s stock price was $18.33.

Exelixis Inc is up 4.44% from its previous closing price of $17.55.

During the last market session, Exelixis Inc’s stock traded between $17.44 and $17.75. Currently, there are 323.26 million shares of Exelixis Inc stock available for purchase.

Exelixis Inc’s price-earnings (P/E) ratio is currently at 31.3, which is high compared to the Biotechnology & Medical Research industry median of 10.7. The price-earnings ratio gauges market expectation of future performance by relating a stock’s current share price to its earnings per share.

Exelixis Inc Stock Price History

Exelixis Inc’s (EXEL) price is currently up 7.32% so far this month.

During the month of March, Exelixis Inc’s stock price has reached a high of $18.70 and a low of $16.15.

Over the last year, Exelixis Inc has hit prices as high as $23.40 and as low as $14.87. Year to date, Exelixis Inc’s stock is up 0.27%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Exelixis Inc Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

One of the most common factors that can drastically impact a stock’s price is analyst upgrades and downgrades. When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. However, as of March 17, 2023,, no analysts have changed their rating of Exelixis Inc’s stock over the last month.

Additionally, you'll want to evaluate Exelixis Inc’s financial health and valuation. It is possible for a stock to appear cheap based on one valuation metric but appear expensive on another. It is also possible for one valuation ratio to be associated with outperforming stocks during certain periods of time but not others.

Therefore, AAII developed a composite valuation to help resolve such issues. AAII’s Value Grade analyzes six distinct variables: price-to-sales (P/S) ratio, price-earnings (P/E) ratio, the ratio of enterprise value to earnings before interest, taxes, depreciation and amortization (EV/EBITDA), shareholder yield, price-to-book-value (P/B) ratio and price-to-free-cash-flow (P/FCF) ratio.

Exelixis Inc’s current valuation based on AAII’s Value Grade is a F, which means it is considered to be Ultra Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Exelixis Inc (EXEL) by visiting AAII Stock Evaluator.

Relative Price Strength of Exelixis Inc

Relative price strength addresses the relationship between a stock price’s trend and the price trend of the market. This ratio is expressed as a percentage and helps investors understand a company’s momentum as well as its value. You can use relative price strength to select investments that have been outperforming the market or a specific benchmark.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. The weighted four-quarter relative price strength rank is the relative price change for each of the past four quarters. The most recent quarterly price change is given a weight of 40%, and each of the three previous quarters are given a weighting of 20%.

As of March 17, 2023, Exelixis Inc has a weighted four-quarter relative price strength of 0.91%, which translates to a Momentum Score of 64 and is considered to be Strong.

Want to learn more about how Exelixis Inc is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Exelixis Inc Stock Price: Bottom Line

As of March 20, 2023, Exelixis Inc’s stock price is $18.33, which is up 4.44% from its previous closing price.

At AAII, we stress that investors should never buy or sell a stock solely based on its stock price. Past returns do not guarantee future performance. Therefore, you should consider multiple ratios, fundamentals and analytics before making a decision. Whether you decide it’s a good time to buy or sell Exelixis Inc’s stock based on its stock price forecast is ultimately up to you.

It’s important to understand that stock prices are driven by a variety of factors, but ultimately the price at any given moment is due to the supply and demand in the market. Stock price overviews, like the one you just read, only give you a small snapshot of a company’s performance, value and momentum.

By becoming an A+ Investor subscriber, you will have full access to analytics, grades, stock screens, commentary and more so you can invest with confidence.